The BTN3A2 mRNA content was lower in LUAD patients than that in healthy individuals in subgroup analysis on the basis of gender, race, nodal metastasis, smoking, stages, as well as tumor grade (Figure 2 and Table 1). This evidence concerns the gene BTN3A2 and neoplasm.